ArticleFrontiers in oncology2021
Development and Validation of Subjective Financial Distress Questionnaire (SFDQ): A Patient Reported Outcome Measure for Assessment of Financial Toxicity Among Radiation Oncology Patients.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A systematic review of financial toxicity measurement instruments for cancer patients based on the COSMIN guideline.Journal of patient-reported outcomes · 2026Pooled it
- Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Standardized Assessment of Patient-Reported Outcomes (PRO) Instruments.PharmacoEconomics - open · 2025Pooled it
- Measuring financial toxicity in head and neck cancer: a systematic review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2024Pooled it
- Psychometric properties of self-reported financial toxicity measures in cancer survivors: a systematic review.BMJ open · 2022Pooled it
- Constructing the scale to measure financial toxicity in cancer patients for Low-middle income countries (FT-LM) by using the modified Delphi method.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Development and validation of the subjective financial distress scale for cancer patients.BMC psychology · 2026Article
- Sociodemographic Factors related to Financial Toxicity among Cancer Patients and Survivors:"The Second Cancer Patient Experience Survey" - A Nationwide Study in Japan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Screening tools to assess cancer-related financial toxicity: a scoping systematic review and thematic analysis protocol.Frontiers in medicine · 2026Article
- Article
- Financial Toxicity Among Cancer Patients in Slovenia.Cancer medicine · 2025Article
- Cross-Cultural Validation of the COmprehensive Score for Financial Toxicity (COST) Measure in an Australian Sample.Cancer medicine · 2025Article
- Development of A Caregiver-Reported Scale for Pediatric Cancer Financial Toxicity (CRS-PCFT).Cancer medicine · 2025Article
- Validity, test-retest reliability, and responsiveness of the Indonesian version of FACIT-COST measure for subjective financial toxicity.Health and quality of life outcomes · 2024Article
- Chinese expert consensus on an innovative patient-centered approach to diagnosis and treatment of cancer.Cancer innovation · 2024Article
- Financial Toxicity in Radiation Oncology.Cureus · 2024Review
- Financial Health of People Living With Dementia and Their Informal Care Partners: Protocol for a Mixed Methods Study.JMIR research protocols · 2023Article
- The development and validation of a patient-reported outcome measure to assess financial hardship among older cancer survivors in China: hardship and recovery with distress survey.Frontiers in oncology · 2023Article
- Shared burden: the association between cancer diagnosis, financial toxicity, and healthcare cost-related coping mechanisms by family members of non-elderly patients in the USA.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Financial toxicity in lung cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFinancial toxicity is a consequence of subjective financial distress experienced by cancer patients as a result of treatment expenditures. Financial toxicity has been associated with poor quality of life, early mortality, and non-adherence. It is evident from the literature that the currently available instruments for the assessment of financial toxicity do not measure coping and support seeking domains. The aim of this study was to develop an instrument for the assessment of financial toxicity among radiation oncology patients that captures and integrates all the relevant domains of subjective financial distress. MATERIALS AND
methodsThe study was conducted among Head & Neck cancer (HNC) patients (age ≥18 years) who have completed the radiotherapy either as stand-alone or part of a multimodal treatment. Literature review, expert opinion, and patient interviews were used for scale item generation. The validity and underlying factor structure were evaluated by Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA). The reliability and internal consistency of the final scale was assessed using Cronbach's alpha coefficient.
resultsA total of 17 items were identified for scale development. The preliminary 17-item instrument was administered to 142 HNC patients. Among 142 participants, 85.9% were male and 98.6% were from rural areas. EFA was performed on 17 items and three items were removed (factor loadings <0.5). The remaining 14 items loaded onto three factors (eigenvalue >1) explaining 62.0% of the total variance. The Chi-square goodness of fit test in CFA and the values of other model fit indices, namely, RMSEA = 0.045, SRMR = 0.014, GFI = 0.92, CFI = 0.98, and TLI=0.97 indicate a good model fit suggesting the three-factor model adequately fits the data. The Cronbach's α for the final 14-item scale was 0.87 indicating excellent reliability and the Cronbach's α coefficient of all the individual 14 items was ≥0.85 (range 0.85-0.88).
conclusionThe SFDQ showed excellent validity and reliability. SFDQ captures and integrates all the relevant domains of financial toxicity. However, the provisional SFDQ instrument warrants further larger sample studies for validation and psychometric evaluation in different primary cancer subsites and treatment modalities from multiple cancer centers to improve the generalizability of this instrument.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.